James Fogarty
About James P. Fogarty
Independent director of Darden Restaurants since 2014 (tenure ~11 years in FY2025), age 57. He currently serves as CEO of FULLBEAUTY Brands (private), and is recognized by Darden’s Nominating & Governance Committee for operational and turnaround expertise with significant C‑suite experience across public and private companies. In FY2025 he chairs the Finance Committee and is a member of Nominating & Governance; the Board has affirmed his independence under NYSE rules (eight of nine nominees are independent). The Board met five times in FY2025; each incumbent director, including Fogarty, attended at least 75% of Board and committee meetings, and the Board held executive sessions at each quarterly meeting .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| FULLBEAUTY Brands, Inc. | CEO | Since June 2019 | Operational leadership of multi-channel apparel/home retailer |
| Orchard Brands | CEO & Director | 2011–2015 | Led through sale; post‑sale Senior Advisor to Bluestem Group Inc. in 2015 |
| Private Investor | Investor | 2010–2011 | Turnaround/portfolio focus |
| Charming Shoppes, Inc. | President, CEO & Director | 2009–2010 | Specialty apparel retail leadership |
| Alvarez & Marsal | Managing Director | 1994–2009 | Restructuring/turnaround specialist |
| Lehman Brothers Holdings | President & COO (post‑Chapter 11) | 2008–2009 | Crisis operations leadership |
| American Italian Pasta Co. | President & CEO | 2005–2008 | Consumer staples operations |
| Levi Strauss & Co. | CFO | 2003–2005 | Finance leadership at global brand |
| The Warnaco Group | SVP & CFO; Director (for a period) | 2001–2003 | Apparel finance and governance |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Current public company boards | None | — | No current public directorships |
| Assertio Therapeutics, Inc. (formerly Depomed) | Chairman of the Board | 2016–2020 | Prior public board service within past five years |
Board Governance
-
Committee assignments by year:
Committee FY2023 FY2024 FY2025 Compensation Chair Chair; committee met 5x, independent membership Member (Comp Chair is T. Wilmott) Finance Member Member Chair Nominating & Governance Member Member Member Audit — — — -
Independence: Board affirmed Fogarty is independent (only CEO Cardenas is non‑independent in FY2025) .
-
Attendance and engagement: Board met five times in FY2025; each incumbent director attended ≥75% of combined Board/committee meetings; executive sessions held at each quarterly meeting .
-
Director compensation oversight: Nominating & Governance Committee uses Pearl Meyer (independent consultant) to review director compensation; all non‑employee directors deemed independent; program draws RSUs from shareholder‑approved plan .
-
Related‑party policy: N&G reviews conflicts; Board must pre‑approve “Interested Transactions” >$120k; no related‑party transactions required to be reported for FY2025; Board concluded any ordinary‑course transactions with entities affiliated with directors were immaterial .
-
Say‑on‑pay support (signal of compensation governance):
Year of Meeting Approval (% of votes cast) 2022 ~95.9% 2023 ~96.5% 2024 ~95.17%
Fixed Compensation
-
Current Director Compensation Program (effective since Sept 2023):
Component Amount Annual cash retainer (all directors) $100,000 Annual equity grant (RSUs) $185,000 fair value Committee chair retainers Audit $35,000; Compensation $25,000; N&G $20,000; Finance $15,000 Committee member retainers Audit $17,500; Compensation $12,500; N&G $10,000; Finance $7,500 Chair of the Board $100,000 cash + $100,000 RSUs Lead Independent Director $60,000 RSUs -
Fogarty’s reported director compensation:
Metric FY2023 FY2025 Fees Earned or Paid in Cash ($) $125,934 $119,931 Stock Awards ($) $160,030 $184,921 Option Awards ($) — — All Other Compensation ($) $4,799 (dividend equivalents) $44,265 (dividend equivalents) Total ($) $290,763 $349,118
Performance Compensation
-
Annual director RSU grants and vesting:
Metric FY2023 FY2024 FY2025 RSU units granted 1,219 (all non‑chair directors) 1,171 (all non‑chair directors) 1,162 (all non‑chair directors) Grant date Sep 21, 2022 Sep 20, 2023 Sep 18, 2024 Grant date fair value ($) $160,030 $175,018 $184,921 Vesting terms Earlier of 1 year or next annual meeting Earlier of 1 year or next annual meeting Earlier of 1 year or next annual meeting -
Dividend equivalents (Fogarty):
Metric FY2024 FY2025 RSUs that vested – dividend equivalents ($) $23,922.46 $6,241 Deferred stock units – dividend equivalents ($) $35,580 $38,024
Directors may elect to receive immediately vested RSUs in lieu of cash fees (settlement may be deferred); RSUs earn dividend equivalents to the extent they vest .
Other Directorships & Interlocks
| Item | Detail |
|---|---|
| Current public boards | None |
| Prior public boards (past 5 years) | Assertio Therapeutics, Inc., Chairman (2016–2020) |
| Compensation Committee interlocks | None; no insider participation or reciprocal interlocks reported in FY2023 |
Expertise & Qualifications
- N&G Committee concluded Fogarty is qualified due to operational and turnaround experience and significant executive officer/director experience across public and private companies .
- Extensive C‑suite finance and operations background (CFO at Levi Strauss; CEO roles at American Italian Pasta, Charming Shoppes; Managing Director at Alvarez & Marsal; crisis COO at Lehman Brothers Holdings) .
Equity Ownership
| Metric | Value |
|---|---|
| Beneficial ownership (common shares), as of May 25, 2025 | 32,176 shares; less than 1% of shares outstanding |
| RSUs counted in beneficial ownership (vested/will vest within 60 days) | 6,790 units |
| Outstanding RSUs (awards outstanding), as of May 25, 2025 | 7,952 units |
| Outstanding RSUs trend | FY2023: 9,189 ; FY2024: 7,961 ; FY2025: 7,952 |
| Stock ownership guidelines | ≥5x annual cash retainer; mandatory hold until compliance; all directors in compliance or on track as of May 25, 2025 |
| Hedging/Pledging | Prohibited for directors; short sales and derivatives prohibited; pledging or margin accounts prohibited |
Governance Assessment
- Committee leadership and expertise: Fogarty’s transition from Compensation Chair (FY2023–FY2024) to Finance Chair (FY2025) aligns with his finance/turnaround background; Compensation Committee remained fully independent with defined processes and no interlocks, supporting pay governance quality .
- Independence and attendance: Affirmed independent; attended ≥75% of meetings; Board held regular executive sessions — positive engagement signals .
- Director pay structure and alignment: Pay mix emphasizes equity via annual RSUs with simple time‑based vesting; Fogarty’s FY2025 pay comprised $119,931 cash fees and $184,921 stock awards, plus $44,265 dividend equivalents — consistent with the standardized program and use of RSUs to align with shareholders .
- Ownership and risk controls: Beneficial ownership of 32,176 shares, RSU accumulation, compliance/on‑track with ownership guidelines, and strict bans on hedging/pledging reduce misalignment risk; no related‑party transactions required to be reported in FY2025 .
- Shareholder confidence indicators: Strong say‑on‑pay approvals (95–96% range across recent years) support investor confidence in compensation oversight during Fogarty’s tenure on Compensation and Finance committees .
RED FLAGS: None disclosed — no related‑party transactions, no hedging/pledging, attendance threshold met, and committee independence affirmed .